Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects

Texto completo
Autor(es):
Mostrar menos -
Coutinho, Artur M. N. [1] ; Porto, Fabio H. G. [2] ; Duran, Fabio L. S. [3] ; Prando, Silvana [1] ; Ono, Carla R. [1] ; Feitosa, Esther A. A. F. [1] ; Spindola, Livia [2] ; de Oliveira, Maira O. [2] ; do Vale, Patricia H. F. [2] ; Gomes, Helio R. [2] ; Nitrini, Ricardo [2] ; Brucki, Sonia M. D. [2] ; Buchpiguel, Carlos A. [1]
Número total de Autores: 13
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Fac Med, Hosp Clin, Dept Radiol Nucl Med Ctr LIM43, BR-05403010 Sao Paulo - Brazil
[2] Dept Neurol, BR-05403900 Sao Paulo - Brazil
[3] Dept Psychiat, BR-01060970 Sao Paulo - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: ALZHEIMERS RESEARCH & THERAPY; v. 7, SEP 15 2015.
Citações Web of Science: 6
Resumo

Introduction: Mild cognitive impairment (MCI) is classically considered a transitional stage between normal aging and dementia. Non-amnestic MCI (naMCI) patients, however, typically demonstrate cognitive deficits other than memory decline. Furthermore, as a group, naMCI have a lower rate of an eventual dementia diagnosis as compared to amnestic subtypes of MCI (aMCI). Unfortunately, studies investigating biomarker profiles of naMCI are scarce. The study objective was to investigate the regional brain glucose metabolism (rBGM) with {[}F-18]FDG-PET and cerebrospinal fluid (CSF) biomarkers in subjects with naMCI as compared to a control group (CG) and aMCI subjects. Methods: Ninety-five patients were included in three different groups: naMCI (N = 32), aMCI (N = 33) and CG (N = 30). Patients underwent brain MRI and {[}F-18]FDG-PET. A subsample (naMCI = 26, aMCI = 28) also had an assessment of amyloid-beta, tau, and phosphorylated tau levels in the CSF. Results: Both MCI groups had lower rBGM in relation to the CG in the precuneus. Subjects with naMCI showed decreased right prefrontal metabolism as well as higher levels of CSF amyloid-beta relative to aMCI subjects. Conclusion: While amnestic MCI subjects showed a biomarker profile classically related to MCI due to Alzheimer's disease, naMCI patients illustrated a decrease in both prefrontal hypometabolism and higher CSF amyloid-beta levels relative to the aMCI group. These biomarker findings indicate that naMCI is probably a heterogeneous group with similar precuneus hypometabolism compared to aMCI, but additional frontal hypometabolism and less amyloid-beta deposition in the brain. Clinical follow-up and reappraisal of biomarkers of the naMCI group is needed to determine the outcome and probable etiological diagnosis. (AU)

Processo FAPESP: 09/17398-1 - Análise de correlação de alterações volumétricas, metabólicas e perfusionais na Doença de Alzheimer, no comprometimento cognitivo leve, e no envelhecimento normal
Beneficiário:Carlos Alberto Buchpiguel
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 11/18245-4 - Fatores preditores da resposta cognitiva em indivíduos com comprometimento cognitivo leve submetidos à atividade física aeróbica
Beneficiário:Sonia Maria Dozzi Brucki
Linha de fomento: Auxílio à Pesquisa - Regular